Mechanism of action

Acoramidis selectively binds to transthyretin (TTR) at the thyroxine‑binding sites.
Stabilizes the TTR tetramer, preventing dissociation into misfolded monomers.
This inhibition prevents amyloid fibril formation and cardiac amyloid deposition.
Demonstrates >90% TTR stabilization across wild‑type and variant TTR genotypes.

Indication

Indicated to reduce cardiovascular death and cardiovascular‑related hospitalization in adult patients with:

Wild‑type or variant transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM)